Press Releases

Date Title
Toggle Summary Faheem Hasnain joins Kura Oncology's Board of Directors
LA JOLLA, April 27, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the appointment of Faheem Hasnain to the Company’s board of
Toggle Summary Kura Oncology Added to Nasdaq Biotechnology Index
SAN DIEGO , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI),
Toggle Summary Kura Oncology Added to Russell 3000® Index
LA JOLLA, Calif. , June 26, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been added to the broad U.S.
Toggle Summary Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors
Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for
Toggle Summary Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO , July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, including
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
Toggle Summary Kura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting
Tipifarnib as Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients With High Risk Disease LA JOLLA, Calif. , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from
Toggle Summary Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting
LA JOLLA, Calif. , June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that preliminary data from the ongoing Phase 2 clinical trial evaluating the efficacy,
Toggle Summary Kura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer
LA JOLLA, Calif. , Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), today announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, an inhibitor of protein farnesylation, in cancer patients with urothelial